Literature DB >> 12414897

Pregnancy-associated plasma protein A proteolytic activity is associated with the human placental trophoblast cell membrane.

Irene Y C Sun1, Michael T Overgaard, Claus Oxvig, Linda C Giudice.   

Abstract

Pregnancy-associated plasma protein-A (PAPP-A) is a product of the placenta and decidua and is secreted into the maternal circulation during human pregnancy. It recently has been identified as an IGF binding protein (IGFBP)-4 protease. Presumed functions at the maternal-fetal interface are to proteolyze IGFBP-4 and thus increase IGF bioavailability locally in the placenta, to promote IGF-II-mediated trophoblast invasion into the maternal decidua, and to modulate IGF regulation of steroidogenesis and glucose and amino acid transport in the villous. Herein, we have investigated the possibility that IGFBP-4 proteolysis may occur on the trophoblast cell membrane, presumably to increase local bioavailable IGF for interactions with cognate IGF membrane receptors. Human trophoblasts were cultured, trophoblast plasma membranes were isolated and solubilized, and IGFBP-4 protease activity and PAPP-A immunoreactivity in the solubilized plasma membrane fraction were investigated. IGFBP-4 protease activity was detected in solubilized human trophoblast membranes, resulting in cleavage of recombinant human IGFBP-4 into 18- and 14-kDa fragments, detected by Western immunoblot analysis. This protease activity was dependent on the presence of IGF-II, and its metal ion dependence was demonstrated by inhibition of the protease by the metal chelators, EDTA and EGTA. The presence of PAPP-A in solubilized human trophoblast membranes was demonstrated by Western immunoblotting. Trophoblast membrane PAPP-A had a relative molecular weight of approximately 200 kDa and comigrated on (reducing) SDS-PAGE with recombinant human PAPP-A and PAPP-A secreted into media conditioned by cultured human trophoblasts. IGFBP-4 protease activity was not detected after immunodepletion of PAPP-A from the trophoblast membrane fraction with PAPP-A polyclonal antibodies, suggesting the identity of the membrane-derived IGFBP-4 protease as PAPP-A. Immunocytochemistry revealed PAPP-A on the cell membrane and in the cytoplasm of human trophoblasts in culture. Together, these data demonstrate the presence of an IGF-II- and metal-dependent IGFBP-4 protease activity in human trophoblast plasma membranes, identified as PAPP-A, which is well situated to proteolyze IGFBP-4 at the maternal-placental interface to facilitate IGF action at the villous surface and/or the invading extravillous cytotrophoblast.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414897     DOI: 10.1210/jc.2002-020561

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Gene expression patterns in human placenta.

Authors:  Ruchira Sood; James L Zehnder; Maurice L Druzin; Patrick O Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

2.  Effects of mutated pregnancy-associated plasma protein-a on atherosclerotic lesion development in mice.

Authors:  Henning B Boldt; Laurie K Bale; Zachary T Resch; Claus Oxvig; Michael T Overgaard; Cheryl A Conover
Journal:  Endocrinology       Date:  2012-11-16       Impact factor: 4.736

3.  Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia.

Authors:  Suchaya Luewan; Monrudee Teja-Intr; Supatra Sirichotiyakul; Theera Tongsong
Journal:  Singapore Med J       Date:  2017-04-28       Impact factor: 1.858

4.  Altered placental expression of PAPPA2 does not affect birth weight in mice.

Authors:  Pamela K Wagner; Julian K Christians
Journal:  Reprod Biol Endocrinol       Date:  2010-07-20       Impact factor: 5.211

5.  Regional variation in adipogenesis and IGF regulatory proteins in the fetal baboon.

Authors:  Yourka D Tchoukalova; Peter W Nathanielsz; Cheryl A Conover; Steven R Smith; Eric Ravussin
Journal:  Biochem Biophys Res Commun       Date:  2009-01-29       Impact factor: 3.575

6.  Transcription enhancer factor-5 and a GATA-like protein determine placental-specific expression of the Type I human 3beta-hydroxysteroid dehydrogenase gene, HSD3B1.

Authors:  Lihong Peng; Yong Huang; Fan Jin; Shi-Wen Jiang; Anita H Payne
Journal:  Mol Endocrinol       Date:  2004-05-06

7.  Prediction of adverse pregnancy outcomes by extreme values of first trimester screening markers.

Authors:  Marina S Gomes; Mariana Carlos-Alves; Vera Trocado; Diana Arteiro; Paula Pinheiro
Journal:  Obstet Med       Date:  2017-05-16

8.  Genome-wide expression profile of first trimester villous and extravillous human trophoblast cells.

Authors:  R Apps; A Sharkey; L Gardner; V Male; M Trotter; N Miller; R North; S Founds; A Moffett
Journal:  Placenta       Date:  2010-11-13       Impact factor: 3.481

9.  First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia.

Authors:  Aditi R Saxena; Ellen W Seely; Janet W Rich-Edwards; Louise E Wilkins-Haug; S Ananth Karumanchi; Thomas F McElrath
Journal:  BMC Pregnancy Childbirth       Date:  2013-04-04       Impact factor: 3.007

10.  Abnormal proinflammatory and stressor environmental with increased the regulatory cellular IGF-1/PAPP-A/STC and Wnt-1/β-Catenin canonical pathway in placenta of women with Chronic venous Disease during Pregnancy.

Authors:  Miguel A Ortega; Oscar Fraile-Martínez; Miguel A Saez; Miguel A Álvarez-Mon; Ana M Gómez-Lahoz; Coral Bravo; Juan A De León Luis; Felipe Sainz; Santiago Coca; Ángel Asúnsolo; Jorge Monserrat; Luis G Guijarro; Melchor Álvarez-Mon; Julia Bujan; Natalio García-Honduvilla
Journal:  Int J Med Sci       Date:  2021-05-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.